310
Participants
Start Date
September 15, 2025
Primary Completion Date
September 15, 2031
Study Completion Date
September 15, 2031
Additional blood collection during routine blood sampling at the inclusion (33.9 ml) and at the thrombotic recurrence (between 3.5 and 5 ml)
"At inclusion, the blood sample is used to perform thrombin generation tests (activated protein C resistance profile and ratio), classical and innovative aPL assays centrally to limit the fluctuation inherent in the tests used and enable comparison between patients, immunothrombosis markers: circulating neutrophil extracellular traps (NETs) assay, sTREM-1 assay~In the event of recurrence, blood sampling can be used to confirm compliance with treatment by measuring the anti Xa activity of the drug or INR"
Completion of a questionnaire on compliance with anticoagulant treatment
The Girerd questionnaire (6 questions) will be proposed to patients in order to estimate the degree of compliance with AODs and VKAs at inclusion and at each follow-up visit for the duration of their participation in the study.
Completion of a questionnaire on satisfaction with treatment anticoagulant
The ACTS questionnaire (15 questions) will be proposed to them in order to estimate their satisfaction with their anticoagulant treatment (AOD or AVK) at inclusion and at each follow-up visit for the duration of their participation in the study.
CHU de Dijon, Dijon
CHU de Besançon, Besançon
CHU de Brest, Brest
CHU de Saint Etienne, Saint-Priest-en-Jarez
CHU de Nantes, Nantes
CHU de Reims, Reims
Central Hospital, Nancy, France, Vandœuvre-lès-Nancy
Hôpital Robert Schuman, UNEOS, Metz
CHU de Strasbourg - Hôpital civil, Strasbourg
CH de Mulhouse, Mulhouse
CHU de Lyon, Lyon
Hôpital Lariboisière - APHP, Paris
CHU d'Amiens, Amiens
Central Hospital, Nancy, France
OTHER